Relmada Therapeutics (RLMD) Receivables (2022 - 2026)
Relmada Therapeutics (RLMD) posted quarterly Receivables of $1.0 million for Q4 2022, down 71.6% quarter-over-quarter from $3.6 million in Q1 2022.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Receivables (2022 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Receivables for 2 consecutive years, with $1.0 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Receivables changed N/A year-over-year to $1.0 million; the TTM figure through Dec 2022 stood at $1.0 million (changed N/A YoY), while the FY2022 annual figure was $1.0 million, changed N/A from the prior year.
- Receivables declined to $1.0 million in Q4 2022 per RLMD's latest filing, from $3.6 million in the prior quarter.
- Across five years, Receivables topped out at $3.6 million in Q1 2022 and bottomed at $1.0 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | 10,912.00 |